Early detection and screening of lung cancer.

Date publication

septembre 2010

Journal

Expert review of molecular diagnostics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/20843203

Résumé

Accounting for 28% of all cancer deaths and causing 1.3 million deaths worldwide every year, lung cancer is the most lethal cancer. Diagnosing and treating cancer at its early stages, ideally during precancerous stages, could increase the 5-year survival rate by three- to four-fold with a potential for cure. Thus far, no screening method has been shown to decrease disease-specific mortality rate. The present review describes the rationale and issues related to early lung cancer screening, the management of screen-detected primary cancers and different approaches that have been tested for screening. These include imaging techniques, bronchoscopies, molecular screenings from different noninvasive or invasive sources, such as blood, sputum, bronchoscopic samples and exhaled breath.

Mots clés

Antibodies, Neoplasm, immunology, Antigens, Neoplasm, metabolism, Bronchoscopy, Clinical Trials as Topic, Early Detection of Cancer, methods, Humans, Lung Neoplasms, diagnosis, Mass Screening, methods, Molecular Diagnostic Techniques, Sputum, chemistry

Référence

Expert Rev. Mol. Diagn.. 2010 Sep;10(6):799-815